MCP App Store
Life-Sciences

ChEMBL

by Anthropic

Overview

The ChEMBL Connector gives Claude access to the ChEMBL Database, a manually curated resource of bioactive drug-like compounds with quantitative binding and functional data against biological targets.

Tools

get_admet

Claude
Retrieve ADMET-related molecular properties for drug-likeness assessment. IMPORTANT: ChEMBL provides CALCULATED molecular properties (from structure), not experimental ADMET data. For experimental ADMET measurements, use get_bioactivity with specific ADMET target ChEMBL IDs. CALCULATED PROPERTIES (what this tool returns): • ALogP: Calculated lipophilicity (Wildman-Crippen LogP) - Optimal for oral drugs: 1-3 - < 0: Poor membrane permeability - > 5: Poor solubility, potential accumulation • Molecular Weight (full_mwt): Total molecular weight including salts • Molecular Weight (mw_freebase): Parent compound molecular weight only • H-bond Donors (HBD): Rule-of-5 limit < 5 • H-bond Acceptors (HBA): Rule-of-5 limit < 10 • Polar Surface Area (PSA): Topological PSA - < 140 Ų: Good oral absorption - < 90 Ų: Better CNS penetration (crosses BBB) • Rotatable Bonds (RTB): < 10 for good oral bioavailability • Heavy Atoms: Non-hydrogen atom count • Aromatic Rings: < 4 recommended for drug-likeness • Rule-of-5 Violations (num_ro5_violations): 0-1 preferred • Rule-of-3 Pass (ro3_pass): Y/N for fragment-like properties • QED Weighted: Quantitative Estimate of Drug-likeness (0-1 scale) - Higher = more drug-like profile - Based on MW, ALogP, HBD, HBA, PSA, RTB, aromatic rings, alerts DRUG-LIKENESS GUIDELINES: • Lipinski Rule-of-5: MW < 500, ALogP < 5, HBD ≤ 5, HBA ≤ 10 • Veber Rules: PSA ≤ 140 Ų, RTB ≤ 10 • Lead-like: MW < 450, ALogP -4 to 4.2, RTB ≤ 10 FOR EXPERIMENTAL ADMET DATA (use get_bioactivity with these targets): • hERG (CHEMBL240): Cardiac safety (K+ channel, IC50 > 10µM preferred) • CYP3A4 (CHEMBL340): Major metabolizing enzyme (avoid strong inhibition) • CYP2D6 (CHEMBL289): Polymorphic CYP (genetic variability concerns) • CYP2C9 (CHEMBL3397): Warfarin metabolism (drug interactions) • P-glycoprotein (CHEMBL4302): Drug efflux transporter (affects BBB, gut) WORKFLOW EXAMPLE: 1. Get calculated properties: get_admet(molecule_chembl_id='CHEMBL941') 2. Check hERG liability: get_bioactivity(molecule_chembl_id='CHEMBL941', target_chembl_id='CHEMBL240') 3. Check CYP inhibition: get_bioactivity(molecule_chembl_id='CHEMBL941', target_chembl_id='CHEMBL340')

get_bioactivity

Claude
Retrieve bioactivity measurements (IC50, Ki, EC50, etc.) for compound-target interactions. WORKFLOW: Use target_search or compound_search first to get ChEMBL IDs, then query bioactivity. ACTIVITY TYPES (standard_type field): • IC50: Half-maximal inhibitory concentration (most common for inhibitors) • Ki: Inhibition constant (binding affinity, independent of substrate concentration) • Kd: Dissociation constant (direct binding measurement) • EC50: Half-maximal effective concentration (for agonists) • AC50: Half-maximal activity concentration • Potency/ED50: Effective dose measurements pChEMBL VALUE (recommended for filtering - standardized potency): • Definition: -log10(molar IC50/Ki/Kd/EC50/AC50/Potency/ED50) • Only calculated when: standard_relation='=' AND standard_units='nM' AND value>0 • pChEMBL 9 = 1 nM (highly potent, drug-like) • pChEMBL 7 = 100 nM (potent) • pChEMBL 6 = 1 µM (moderate) • pChEMBL 5 = 10 µM (weak) • pChEMBL 3 = 1 mM (very weak) • Use min_pchembl >= 6 for µM or better activity • Use min_pchembl >= 7 for sub-100nM potency (drug-like) ASSAY TYPES (assay_type field): • B (Binding): Direct target binding measurements (Ki, Kd) • F (Functional): Biological effect in cells/tissues (EC50, IC50 in cellular context) • A (ADME): Absorption, distribution, metabolism, excretion assays (t1/2, bioavailability) • T (Toxicity): Cytotoxicity, hERG inhibition • P (Physicochemical): Solubility, stability (no biological material) • U (Unclassified): Cannot fit single category DATA VALIDITY FLAGS (data_validity_comment field): • 'Outside typical range': Value unusually high/low for activity type • 'Potential missing data': Incomplete data entry • 'Potential author error': Suspected error in publication • 'Manually validated': Curator confirmed accuracy • 'Potential transcription error': Values differ by 3 or 6 orders of magnitude (unit error) LIGAND EFFICIENCY METRICS (in results when available): • LE (Ligand Efficiency): Activity per heavy atom • BEI (Binding Efficiency Index): Activity per molecular weight • LLE (Lipophilic Ligand Efficiency): pActivity - LogP • SEI (Surface Efficiency Index): Activity per polar surface area TIPS: • Use with ADMET targets to get experimental ADMET data • Combine molecule_chembl_id + target_chembl_id for specific compound-target pairs • Check potential_duplicate flag - may indicate cited (not independent) measurements • activity_comment may indicate 'active'/'inactive' conclusions from depositor • document_chembl_id links to source publication for verification

get_mechanism

Claude
Retrieve mechanism of action (MoA) data for approved drugs and clinical candidates. PURPOSE: Understand how drugs interact with their targets - essential for drug repurposing, understanding polypharmacology, and target validation. ACTION TYPES (action_type field): • INHIBITOR: Blocks target activity (most common for small molecule drugs) • ANTAGONIST: Blocks receptor activation (prevents agonist binding) • AGONIST: Activates receptor (mimics natural ligand) • BLOCKER: Blocks ion channels or transporters • MODULATOR: Alters target activity (often allosteric mechanism) • POSITIVE ALLOSTERIC MODULATOR: Enhances agonist response without binding orthosteric site • NEGATIVE ALLOSTERIC MODULATOR: Reduces agonist response • OPENER: Opens ion channels (increases conductance) • ACTIVATOR: Increases enzyme activity • PARTIAL AGONIST: Partially activates receptor (submaximal efficacy) • INVERSE AGONIST: Reduces constitutive (basal) receptor activity • SUBSTRATE: Acts as substrate for enzyme (e.g., prodrugs) • RELEASING AGENT: Causes release of neurotransmitters • SEQUESTERING AGENT: Binds and removes target (e.g., antibodies) KEY RESULT FIELDS: • direct_interaction: true = drug binds directly to target; false = indirect effect • disease_efficacy: true = target is directly relevant to therapeutic effect • molecular_mechanism: Specific molecular action (e.g., 'Cyclooxygenase inhibitor') • binding_site_name/comment: Where drug binds on target (e.g., 'ATP binding site') • selectivity_comment: Notes on target selectivity vs related proteins • mechanism_refs: Literature references supporting the mechanism BINDING SITE INFORMATION: Results may include binding site details when known: • site_name: Named binding pocket (e.g., 'Colchicine site', 'ATP binding domain') • site_id: ChEMBL binding site identifier for further lookup WORKFLOW: 1. Find compound: compound_search(name='imatinib') 2. Get mechanisms: get_mechanism(molecule_chembl_id='CHEMBL941') 3. Validate with bioactivity: get_bioactivity(molecule_chembl_id='CHEMBL941', target_chembl_id='CHEMBL1862') TIPS: • MoA data is manually curated for approved drugs and advanced clinical candidates • Use target_chembl_id to find all drugs acting on a specific target (drug repurposing) • Check mechanism_refs for original publications supporting the mechanism • Combine with get_bioactivity to see quantitative potency data for mechanism targets • Parent compound IDs work even when mechanism is stored under salt form

App Stats

6

Tools

Claude

Platforms

Works with

Claude

Data refreshed daily